Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India

• Príomhchruthaitheoirí: Sharad Agarkhedkar (Údar), Jugesh Chhatwal (Údar), Rajeev Zachariah Kompithra (Údar), Sanjay K. Lalwani (Údar), Arun Narayan (Údar), Vinay Muninarayanaswam (Údar), Nithya Gogtay (Údar), Kristin Dotter (Údar), Viviane Gresset-Bourgeois (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Taylor & Francis Group, 2019-04-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

A quadrivalent split-virion inactivated influenza vaccine (IIV4; Fluzone® Quadrivalent, Sanofi Pasteur) has been available in the US since 2013 for individuals aged ≥ 6 months. Here, we describe the results of an open-label, multicenter trial (WHO Universal Trial Number U1111-1143-8370) evaluating t...